GUILLERMO
LÓPEZ VIVANCO
Forscher bis um 2022
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (3)
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2012
2003
-
Chemotherapy for Bladder Cancer [6] (multiple letters)
New England Journal of Medicine